search
Back to results

Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Primary Purpose

Myelodysplastic Syndromes, Acute Myeloid Leukemia

Status
Unknown status
Phase
Phase 1
Locations
Brazil
Study Type
Interventional
Intervention
Autologous dendritic cells electroporated with WT1 mRNA
Sponsored by
University of Campinas, Brazil
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myelodysplastic Syndromes

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Individuals between the ages of 18 and 70
  • High-risk myelodysplasia (AREB 1 or AREB 2 subtypes) and Acute Myeloid Leukemia
  • Minimum interval of 30 days between the last cycle of chemotherapy (when it occurs) and start of immunotherapy
  • Performance status between 0 and 3 on the WHO (World Health Organization)-ECOG (Eastern Cooperative Oncology Group) scale
  • Calculated creatinine clearance> 30 ml / min using the Cockcroft-Gault formula
  • Total bilirubin less than or equal to twice the lower limit of the normal range in the institution and aspartate aminotransferase (AST) less than or equal to twice the upper limit of normal
  • Absence of blasts in peripheral blood
  • Leukocyte count greater than 3000 cells / mm3, hemoglobin greater than 9.0 g / dl and platelets greater than 70,000 platelets / mm3, if possible. (If the patient does not meet these criteria for apheresis, the possibility of transfusion of blood components after leukapheresis will be proposed and the patient should sign a specific term of science on the possibility of transfusion)
  • Normal cardiac evaluation
  • Negative serologies for hepatitis B and C viruses and HIV
  • Written informed consent form signed before entering the study

Exclusion Criteria:

  • Does not meet any of the requirements of the inclusion criteria
  • Low risk myelodysplasia by IPSS (International Prognostic Scoring System) or WPSS (WHO adapted Prognostic Scoring System) scores
  • Individuals with a history of any previous neoplasia, except those with prolonged clinical remission (more than 5 years) of non-melanoma skin cancers and cervical cancer in situ
  • Pregnant or lactating women
  • Previous immunotherapy or biological therapy

Sites / Locations

  • Hematology and Transfusion Medicine Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients

Arm Description

High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia

Outcomes

Primary Outcome Measures

Disease free survival

Secondary Outcome Measures

Full Information

First Posted
March 12, 2017
Last Updated
October 9, 2020
Sponsor
University of Campinas, Brazil
search

1. Study Identification

Unique Protocol Identification Number
NCT03083054
Brief Title
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Official Title
Cellular Immunotherapy as a Treatment Option for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 2016 (Actual)
Primary Completion Date
July 12, 2020 (Actual)
Study Completion Date
July 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Campinas, Brazil

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of this work is to conduct a clinical study for the development and application of a vaccine with autologous dendritic cells submitted to electroporation with Wilm's tumor 1 (WT1) messenger ribonucleic acid (mRNA), as an adjuvant treatment of high-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia, aiming to delay the progression of the disease or its relapse and increase overall and event-free survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelodysplastic Syndromes, Acute Myeloid Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patients
Arm Type
Experimental
Arm Description
High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
Intervention Type
Biological
Intervention Name(s)
Autologous dendritic cells electroporated with WT1 mRNA
Intervention Description
Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
Primary Outcome Measure Information:
Title
Disease free survival
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individuals between the ages of 18 and 70 High-risk myelodysplasia (AREB 1 or AREB 2 subtypes) and Acute Myeloid Leukemia Minimum interval of 30 days between the last cycle of chemotherapy (when it occurs) and start of immunotherapy Performance status between 0 and 3 on the WHO (World Health Organization)-ECOG (Eastern Cooperative Oncology Group) scale Calculated creatinine clearance> 30 ml / min using the Cockcroft-Gault formula Total bilirubin less than or equal to twice the lower limit of the normal range in the institution and aspartate aminotransferase (AST) less than or equal to twice the upper limit of normal Absence of blasts in peripheral blood Leukocyte count greater than 3000 cells / mm3, hemoglobin greater than 9.0 g / dl and platelets greater than 70,000 platelets / mm3, if possible. (If the patient does not meet these criteria for apheresis, the possibility of transfusion of blood components after leukapheresis will be proposed and the patient should sign a specific term of science on the possibility of transfusion) Normal cardiac evaluation Negative serologies for hepatitis B and C viruses and HIV Written informed consent form signed before entering the study Exclusion Criteria: Does not meet any of the requirements of the inclusion criteria Low risk myelodysplasia by IPSS (International Prognostic Scoring System) or WPSS (WHO adapted Prognostic Scoring System) scores Individuals with a history of any previous neoplasia, except those with prolonged clinical remission (more than 5 years) of non-melanoma skin cancers and cervical cancer in situ Pregnant or lactating women Previous immunotherapy or biological therapy
Facility Information:
Facility Name
Hematology and Transfusion Medicine Center
City
Campinas
State/Province
São Paulo
ZIP/Postal Code
13083-870
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

We'll reach out to this number within 24 hrs